ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2230

Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study

Yiming Luo1, Marcela Ferrada1, Keith Sikora2, Daniel Kastner3, Zuoming Deng4, Mengqi Zhang5, Hugh Alessi1, Virginia Kraus6, Andrew Allen6 and Peter Grayson7, 1National Institutes of Health, Bethesda, MD, 2National Institutes of Health Clinical Center, Bethesda, MD, 3National Human Genome Research Institute, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5University of Pennsylvania, Philadelphia, PA, 6Duke University, Durham, NC, 7National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

Meeting: ACR Convergence 2022

Keywords: cartilage, genetics, genomics, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders II

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Relapsing polychondritis (RP) is a rare rheumatic disease of unknown etiology characterized by inflammations of cartilaginous structures and other tissues, particularly the ears, nose, joints, airway, and blood vessels. Familial clustering in RP has been observed, which suggests a possible causal role of germline genetic variation. The objective of this study was to examine the contribution of ultra-rare genetic variations in RP. We hypothesized that ultra-rare genetic variants with large deleterious effects contribute to the development of RP.

Methods: We performed a case-control exome-wide rare variant association analysis including 66 unrelated RP cases and 2923 sex-matched controls of Caucasian ancestry. Stringent quality control steps were used to select high-quality exonic variants with balanced coverage between cases and controls. Principal component analysis and identity-by-descent analysis was performed to confirm biological unrelatedness and ancestry homogeneity. Five collapsing models were designed based on variant allele frequency in the Genome Aggregation Database (gnomAD) and predicted deleterious effects based on Combined Annotation Dependent Depletion (CADD) scoring. Gene-level collapsing analysis was performed using Firth’s logistics regression adjusting for sex and first 3 principal components. Pathway analysis was performed on the “Hallmark Gene Sets” from the Molecular Signatures Database with three different methods: Gene Set Enrichment Analysis (GSEA), sequence kernel association test (SKAT), higher criticism (HC) test. The HC test was performed with both unweighted and weighted approach. The weighted HC test allows incorporation of external information including gene intolerance metrics and centrality measures in protein interaction networks. The weight was based on the Residual Variation Intolerance Score (RVIS), degree centrality, eigenvector centrality and RankPage centrality, respectively. The gene interaction data from the bioGRID database was used to calculate centrality.

Results: In the collapsing analysis, RP was associated with a significantly higher burden of ultra-rare damaging variants in the DCBLD2 gene (7.6% vs 0.1%, p = 2.93 x 10-7) compared to controls. Patients with RP with ultra-rare damaging variants in DCBLD2 had a numerically higher prevalence of cardiovascular manifestations, including cardiac involvement, aortitis, Raynaud phenomena and venous thromboembolism, compared to other patients with RP. Pathway analysis showed statistically significant enrichment of genes in the tumor necrosis factor (TNF) signaling pathway by the HC test weighted by degree and eigenvector centrality in the ultra-rare damaging (p = 0.039 and p < 0.001, weighted by degree and eigenvector centrality respectively) and rare damaging models (p = 0.039 and p < 0.001, weighted by degree and eigenvector centrality respectively).

Conclusion: This study identified specific rare variants in DCBLD2 as putative genetic risk factors for RP. Rare genetic variation within the TNF pathway is also potentially associated with development of RP. These findings should be validated in additional patients with RP and supported by future functional experiments.


Disclosures: Y. Luo, None; M. Ferrada, None; K. Sikora, Horizon Therapeutics; D. Kastner, None; Z. Deng, None; M. Zhang, None; H. Alessi, None; V. Kraus, Trialspark, GlaxoSmithKlein(GSK), Novartis, Zimmer Biomet, Nordic Bioscience Clinical Development A/S, 23andME; A. Allen, None; P. Grayson, None.

To cite this abstract in AMA style:

Luo Y, Ferrada M, Sikora K, Kastner D, Deng Z, Zhang M, Alessi H, Kraus V, Allen A, Grayson P. Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/ultra-rare-genetic-variation-in-relapsing-polychondritis-a-whole-exome-sequencing-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultra-rare-genetic-variation-in-relapsing-polychondritis-a-whole-exome-sequencing-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology